BioVaxys Technology Corp.
BioVaxys Technology Corp.
Indice CSE:
Devise:
BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.
BioVaxys Technology Corp. (BIOV)
(%)
*Financial charts powered by Quotemedia.com. All right reserved. View the Terms of Use. Data delayed 15 minutes unless indicated.
Information d'entreprise
Addresse
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
CanadaTéléphone
646-452-7000Courriel
jpassin@biovaxys.comURL
https://biovaxys.com/Date d’inscription à la cote
Mercredi, novembre 21, 2018
Agent de transfert
Odyssey Trust CompanyCourriel
news@biovaxys.comVérificateur
Dale Matheson Carr-Hilton Labonte LLPSEDAR Information
Type de dossier
Tout
Délai
@count semaine@count mois3 month6 month@count annéeTout le temps
Information d'entreprise
Addresse
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
CanadaTéléphone
646-452-7000Courriel
jpassin@biovaxys.comURL
https://biovaxys.com/Date d’inscription à la cote
Mercredi, novembre 21, 2018
Agent de transfert
Odyssey Trust CompanyCourriel
news@biovaxys.comVérificateur
Dale Matheson Carr-Hilton Labonte LLPCapitalisation
Capitalisation:
291525203Réservé à l'émission:
139701394Company Officers
James Passin, CEO
Kenneth Kovan, COO & President
Christopher Cherry, Chief Financial Officer
James Passin, Chief Executive Officer
Christopher Cherry, Chief Financial Officer
Kenneth Kovan, Chief Operating Officer and President
Communiqués de presse
Dépôts CSE
